Investment
Features
FeesSafety
Academy
More
Pluang+

Compare JPMorgan Ultra Short Income ETF (JPST) vs Revvity Inc (RVTY) Price & Performance

JPMorgan Ultra Short Income ETFTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

JPMorgan Ultra Short Income ETF vs Revvity Inc — how do they compare? JPMorgan Ultra Short Income ETF trades at $50.46, while Revvity Inc trades at $115.98 (market cap $12.91B). The key difference: Revvity Inc pays a 0.24% dividend while JPMorgan Ultra Short Income ETF pays none, and Revvity Inc is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals.

JPSTRVTY
Sector
Leveraged / InverseTechnology
52-Week High
$50.78$117.75
52-Week Low
$50.40$82.26
Market Cap
$12.91B
Enterprise Value
$15.23B
Dividend Yield
0.24%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

JPMorgan Ultra Short Income ETF

JPST, the JPMorgan Ultra-Short Income ETF, trades at $50.465, up 0.05% with a bearish technical signal. The ETF focuses on high-quality, short-term bonds, offering a cash alternative with consistent dividends. Recent institutional buying includes Financial Management Professionals increasing its stake by 4.7% in Q2 2026 (SEC filing, August 11, 2026).

Outlook remains stable for risk-averse investors seeking yield with low volatility. Key risks include interest rate hikes and inflation pressures, as noted in Fed commentary (Zacks Investment Research, July 31, 2026). The ETF's short duration mitigates rate sensitivity, but macroeconomic shifts could impact returns.

Revvity Inc

RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.

The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.

Returns comparison

Trailing returns across standard periods

About JPMorgan Ultra Short Income ETF

JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.

Read more on JPST

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY